{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:34:29Z","timestamp":1793266469275,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:00:00Z","timestamp":1792886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcpo.2026.100825","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:23:41Z","timestamp":1792772621000},"page":"100825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["International regulatory status and reimbursement recommendations of haematological malignancy drugs withdrawn from the FDA accelerated approval pathway"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3467-6031","authenticated-orcid":false,"given":"Sophie S.","family":"Mulsant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-2666","authenticated-orcid":false,"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-5751","authenticated-orcid":false,"given":"Huseyin","family":"Naci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2026.100825_bib1","unstructured":"Food and Drug Administration, Accelerated Approval. https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval, 2023 (accessed 10 August 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jama.2024.2396","article-title":"Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval","volume":"331","author":"Liu","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jcpo.2026.100825_bib3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jcpo.2026.100825_bib4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.2017.9415","article-title":"Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US food and drug administration","volume":"318","author":"Naci","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jcpo.2026.100825_bib5","doi-asserted-by":"crossref","first-page":"n1959","DOI":"10.1136\/bmj.n1959","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study","author":"Gyawali","year":"2021","journal-title":"BMJ 374"},{"key":"10.1016\/j.jcpo.2026.100825_bib6","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2104846","article-title":"Dangling\u201d accelerated approvals in oncology","volume":"384","author":"Beaver","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2026.100825_bib7","unstructured":"Food and Drug Administration, Accelerated Approval \u2013 Expedited Program for Serious Conditions, Report No. FDA-2024-D-2033. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/accelerated-approval-expedited-program-serious-conditions, 2024 (accessed 8 August 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib8","unstructured":"Food and Drug Administration, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, Report No. FDA-2023-D-0110. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-considerations-support-accelerated-approval-oncology-therapeutics, 2023 (accessed 8 August 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib9","unstructured":"Food and Drug Administration, Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway, Report No. FDA-2024-D-3334. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/accelerated-approval-and-considerations-determining-whether-confirmatory-trial-underway, 2025 (accessed 8 August 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib10","unstructured":"Food and Drug Administration, Withdrawn | Cancer Accelerated Approvals. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/withdrawn-cancer-accelerated-approvals, 2024 (accessed 8 August 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib11","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/S1470-2045(23)00592-2","article-title":"Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications","volume":"25","author":"Koole","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100825_bib12","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1470-2045(24)00025-1","article-title":"Current regulatory status in China of drugs withdrawn from the US FDA accelerated pathway: implications for regulation globally","volume":"25","author":"Luo","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100825_bib13","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1016\/S1470-2045(23)00357-1","article-title":"Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?","volume":"24","author":"Cramer","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100825_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13879","article-title":"Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: a comparative study of accelerated approvals","volume":"17","author":"Hakariya","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jcpo.2026.100825_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(24)02352-3","article-title":"Population-health impact of new drugs recommended by the national institute for health and care excellence in England during 2000\u201320: a retrospective analysis","volume":"405","author":"Naci","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jcpo.2026.100825_bib16","unstructured":"Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm, (accessed 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib17","unstructured":"US National Library of Medicine. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/, (accessed 25 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib18","unstructured":"Office of the Federal Register. Federal Register. https:\/\/www.federalregister.gov, (accessed2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib19","unstructured":"Therapeutic Goods Administration. Provisional approval pathway: prescription medicines. https:\/\/www.tga.gov.au\/provisional-approval-pathway-prescription-medicines, 2018 (accessed 8 August 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib20","series-title":"Guidance Document: Notice of Compliance with Conditions (NOC\/c)","author":"Health Canada","year":"2016"},{"key":"10.1016\/j.jcpo.2026.100825_bib21","unstructured":"European Medicines Agency. Conditional marketing authorization. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/conditional-marketing-authorisation, (accessed 8 August 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib22","unstructured":"Therapeutic Goods Administration. Australian Public Assessment Reports (AusPAR), https:\/\/www.tga.gov.au\/resources\/australian-public-assessment-reports-auspar, (accessed 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib23","unstructured":"Health Canada. Drug and Health Product Portal. https:\/\/dhpp.hpfb-dgpsa.ca\/, (accessed2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib24","unstructured":"European Medicines Agency. Medicines. https:\/\/www.ema.europa.eu\/en\/medicines, (accessed 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib25","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/S1470-2045(24)00434-0","article-title":"Differences in the on-label cancer indications of medicinal products between Europe and the USA","volume":"26","author":"Perini","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100825_bib26","unstructured":"Internet Archive. Wayback Machine. Available online at: https:\/\/Archive.org\/web\/. (accessed 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsad008","article-title":"Lessons from Canada\u2019s notice of compliance with conditions policy for the life-cycle regulation of drugs","volume":"10","author":"McPhail","year":"2023","journal-title":"J. Law Biosci."},{"key":"10.1016\/j.jcpo.2026.100825_bib28","unstructured":"The Pharmaceutical Benefits Scheme. Public Summary Documents by Product https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/public-summary-documents-by-product, (accessed 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib29","unstructured":"Canada\u2019s Drug Agency. Reimbursement Review Reports. https:\/\/www.cda-amc.ca\/reimbursement-review-reports, (accessed 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib30","unstructured":"National Institute for Health and Care Excellence. Search NICE https:\/\/www.nice.org.uk\/, (accessed 26 June 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib31","unstructured":"Medicines and Healthcare products Regulatory Agency. Guidance: International Recognition Procedure. https:\/\/www.gov.uk\/government\/publications\/international-recognition-procedure\/international-recognition-procedure (accessed2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamainternmed.2020.8441","article-title":"Assessment of coverage in England of cancer drugs qualifying for US Food and Drug Administration accelerated approval","volume":"181","author":"Cherla","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jcpo.2026.100825_bib33","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1056\/NEJMp2412068","article-title":"Autopsy of a drug withdrawal \u2013 the case of melphalan flufenamide","volume":"391","author":"Kanapuru","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2026.100825_bib34","unstructured":"Food and Drug Administration, Final Decision on the Proposal to Withdraw Approval of Pepaxto (melphalan flufenamide) for Injection, Report No. FDA-2023-N-3167. https:\/\/www.regulations.gov\/document\/FDA-2023-N-3167-0049, 2024 (accessed 8 August 2025)."},{"key":"10.1016\/j.jcpo.2026.100825_bib35","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1468-0009.12476","article-title":"Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States","volume":"98","author":"Salcher-Konrad","year":"2020","journal-title":"Milbank Q"},{"key":"10.1016\/j.jcpo.2026.100825_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41571-023-00821-7","article-title":"Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma","volume":"21","author":"Cliff","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2026.100825_bib37","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jcpo.2026.100825_bib38","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"Dreyling","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jcpo.2026.100825_bib39","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(25)01432-1","article-title":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2\/3 superiority trial","volume":"406","author":"Lewis","year":"2025","journal-title":"Lancet"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326001268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326001268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:49:59Z","timestamp":1793263799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326001268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":39,"alternative-id":["S2213538326001268"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100825","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International regulatory status and reimbursement recommendations of haematological malignancy drugs withdrawn from the FDA accelerated approval pathway","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100825","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100825"}}